Search Results - ravi+anchoori

3 Results

Sort By:

Anti-cancer "Spirocyclic-guanidine Compounds" and Uses Thereof

Unmet Need / Invention Novelty: Currently available anti-cancer proteasome inhibitors are highly effective against liquid tumors, however, resistance develops. Furthermore, available proteasome inhibitors are not effective against solid tumors. There is an unmet need to develop anti-cancer proteasome inhibitors that overcome these limitations. Technical...

Published: 5/10/2024 | Inventor(s): Richard Roden, Ravi Anchoori

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Novel Bis-benzylidine Piperidone-based Proteasome Inhibitors with Anticancer Activity

Unmet NeedA hallmark of many human cancers is the proteasomal degradation of tumor suppressor proteins, leading to apoptosis arrest and sustained cell proliferation. Yet, to date, the therapeutic use of proteasome inhibitors is impeded by the grave side effects and emergence of disease resistance. This invention provides the novel small molecule proteasome...

Published: 5/9/2024 | Inventor(s): Balasubramanyam Karanam, Ravi Anchoori, Richard Roden

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Candidate Small Molecule Proteasome Inhibitors with Antitumor Properties

Unmet NeedCancer cells differ critically from normal cells, e.g., higher metabolic rates. Proteasomes play a pivotal role in managing excessive metabolism and maintaining protein homeostasis, as the continued over-accumulation of mis-folded proteins is toxic to cells.Several proteasome inhibitors have proven efficacious against hematologic malignancies,...

Published: 5/10/2024 | Inventor(s): Ravi Anchoori, Richard Roden

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules